nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.07.2021 | Infection (K.T. Thakur, Section Editors)

Central Nervous System Infections in Immunocompromised Patients

verfasst von: Amy A. Pruitt

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 7/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This article reviews current epidemiologic trends, clinical presentations, and diagnostic strategies for central nervous system (CNS) infections in human immunodeficiency virus-negative (HIV) patients immunocompromised by their underlying disease or by receipt of immunosuppressive or immunomodulating therapies. Three patient groups are considered: (1) cancer patients; (2) hematopoietic or solid organ transplantation recipients; and (3) patients with autoimmune or inflammatory conditions requiring therapies that alter the host immune response.

Recent Findings

Clinical presentations, associated neuroimaging, and cerebrospinal fluid (CSF) abnormalities differ between immunocompromised and immunocompetent patients. Infections can trigger the emergence of neurotropic antibodies or inflammatory conditions due to treatment with cancer immunotherapies. Unbiased metagenomic assays to identify obscure pathogens help clinicians navigate the increasing range of conditions affecting the growing population of patients with altered immunity.

Summary

Awareness of clinical presentations and disease and drug-specific risks is important for early diagnosis and intervention in these often life-threatening infections and their noninfectious mimes.

•• Sonneville R, Magalhaesa E, Meyfroidt G. Central nervous system infections in immunocompromised patients. Curr Opin Crit Care. 2017;23(2):128–33 Excellent overview of infections in groups including HIV patients.CrossRef

• Mukerji SS, Ard K, Schaefer PW, Branda JA. Case 32-2020: a 63-year-old man with confusion, fatigue, and garbled speech. N Engl J Med. 2020;383:1578–86 An interesting CPC discussion of novel pathogens in the context of a man who developed Borrelia miyamotoi after receipt of prednisone, cyclosporine, and 21 months of rituximab for membranous nephropathy.CrossRef

Stuby J, Herren T, Guidoc SN, Claudiad P, Alain R. Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature. Swiss Med Wkly. 2020;150:w20377 Published 23 November 2020. https://doi.org/10.4414/smw.2020.20377.CrossRefPubMed

• Sechi E, Markovic SN, McKeon A, Duby D, et al. Neurologic autoimmunity and immune checkpoint inhibitors autoantibody profiles and outcomes. Neurology. 2020;95:e2442–52. https://doi.org/10.1212/WNL.000000000001063Discusses the newly recognized phenomena of both central and peripheral neurologic complications of ICIs and the emergence of some of the classic paraneoplastic syndromes in the presence of ICIs.CrossRefPubMed

Armangue T, Leypoldt F, Malaga I, et al. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol. 2014;75(2):317–23.CrossRef

Venkatesan A, Benavides DR. Autoimmune encephalitis and its relation to infection. Curr Neuro Neurosci Rep. 2015;15(3):3. https://doi.org/10.1007/s1910-0150-529-1.CrossRef

Safdieh JE, Mead PA, Sepkowitz KA, et al. Bacterial and fungal meningitis in patients with cancer. Neurology. 2008;70912:943–7.CrossRef

Costerus JM, Brouwer MC, Van der End A, van de Beek D. Community-acquired bacterial meningitis in aduts with cancer or a history of cancer. Neurology. 2016;86(9):860–6. https://doi.org/10.1212/WNL.0000000000002315.CrossRefPubMed

Basic-Jukic N, Juric I, Furic-Cunko V, Kastelani Z. Central nervous system infections in renal transplant recipients. Transpl Infect Dis. 2020;22:e13341.CrossRef

10.

• Perrinjaqueta C, Desbaillets N, Hottinger AF. Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy. Cur Op Neurol. 2019;32(3):500–10 Well-written overall review.CrossRef

11.

Williamson PR, Jarvis JN, Panackal AA, Fisher MC et al. Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy. Nat Rev Neurol 2017;13 https://doi.org/10.1038/nrneurol.2016.167. Published online 25 Nov 2016

12.

Coussement J, Lebeaux D, Rouzaud C, Lortholary O. Nocardia infections in solid organ and hematopoietic stem cell transplant recipients. Curr Opin Infect Dis. 2017;30:545–51.CrossRef

13.

•• Anderson JD, Ho VT, Wright KT, Levy BD, Lascalzo J. Parroting lymphoma. N Engl J Med. 2020;383:1378–81 This is a nice clinical problem-solving case in a 48-year-old man heavily treated for EBV-positive diffuse large B cell lymphoma who presents with fever and headache.

14.

Mishra AK, Arvind VH, Muliyil D, Kuriakose CK, George AA, Karuppusami R, et al. Cerebrovascular injury in cryptococcal meningitis. Int J Stroke. 2018;13:57–65.

15.

Vela-Duarte D, Nyberg E, Silau S, et al. Lacunar stroke in cryptococcal meningitis: clinical and radiographic features. J Stroke Cerebrovasc Dis. 2019;28:1767–72.CrossRef

16.

Soyama A, Eguchi S, Takatsuki M, Ichikawa T, Moriuchi M, Moriuchi H, et al. Human T-cell leukemia virus type 1-associated myelopathy following living donor liver transplantation. Liver Transpl. 2008;14(5):647–50.

17.

Tan IL, McArthur JC, Venkatesan A, Nath A. Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised. Neurology. 2012;79(21):2125–32.CrossRef

18.

Wilson MR, O’Donovan BD, Gelfand JM, Sample HA, Chow FC, Betjemann JP, et al. Chronic meningitis investigated via metagenomic next-generation sequencing. JAMA Neurol. 2018;75:947–55. https://doi.org/10.1001/jamaneurol.2018.0463.

19.

•• Wilson MR, Sample HA, Zorn KC, Arevalo S, Yu G, et al. Clinical metagenomic sequencing for diagnosis of meningitis and encephalitis. N Engl J Med. 2019;380:2327–40. This UCSF laboratory has identified unusual pathogens in undiagnosed meningitis case by finding non-human nucleic acid in CSF specimens.

20.

Ng S, Le Corre M, Aloy E, Gras-Combe G, Duffau H, Boetto J. Herpes simplex encephalitis shortly after surgery for secondary glioblastoma: a case report and review of the literature. Sep. 2019;129:13–7. https://doi.org/10.1016/j.wneu.2019.05.173.CrossRef

21.

Zhao CZ, Erickson J, Dalmau J. Clinical reasoning: agitation and psychosis in a patient after renal transplantation. Neurology. 79:e41–4.

22.

Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations pathophysiology, and outstanding questions. Lancet Neurol. 2015;14(9):914–25.CrossRef

23.

Sueki H, Mizukawa Y, Aoyama Y. Immune reconstitution inflammatory syndrome in non-HIV immunosuppressed patients. J Derm. 2018;45:3–9.CrossRef

24.

Sun HY, Singh N. Opportunistic-infection immune reconstitution inflammatory syndrome in transplant recipients. Clin Infect Dis. 2011;53(2):168–76.CrossRef

25.

• Kunchok A, Aksamit AJ Jr, Davis JM III, et al. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. Published online May 18, 2020. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2020.1162.11. An important series that highlights risk of demyelinating events with TNF-α inhibitors exposure.

26.

Garcia CR, Jayswal R, Adams V, Anthony LB, Villano JL. Multiple sclerosis outcomes after cancer immunotherapy. Clin Transl Oncol. 2019;21(10):1336–42. https://doi.org/10.1007/s12094-019-02060-8.CrossRefPubMedPubMedCentral

27.

•• Larkin J, Chmielowski B, Lado CD, Hodi S, et al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017;22:709–18 The series discusses recently described syndromes and develops diagnostic strategies to distinguish autoimmune from infectious encephalitis.CrossRef

28.

Kaul DR, Covington S, Taranato S, Green M, et al. Solid organ transplant donors with central nervous system infection. Transplantation. 2014;98:666Y670.

29.

Cohen BA, Stosor V. Opportunistic infections of the central nervous system in the transplant patient. Curr Neurol Neursci Rep. 2013;13(9):376.CrossRef

30.

•• Pruitt AA. Infections complicating immunosuppression and transplantation. Continuum. 2018;24(5):1370–96 Comprehensive review with tables and case studies relevant to the subject of this review.PubMed

31.

Baldwin KJ, Cummings CL. Herpesvirus infections of the nervous system. Continuum. 2018;24(5):1349–69.PubMed

32.

Pawlitzki M, Teuber J, Campe C, Wagner M, Schuart C, Paul F, et al. VZV-associated acute retinal necrosis in a patient with MS treated with natalizumab. Neurol Neuroimmunol Neuroinflamm. 2018;5:e475. https://doi.org/10.1212/NXI.0000000000000475.CrossRefPubMedPubMedCentral

33.

Bhanushali MJ, Kranick SM, Freeman AF, Cuellar-Rodriguez JM, Battiwalla M, Gea-Banacloche JC, et al. Human herpes 6 virus encephalitis complicating allogeneic hematopoietic stem cell transplantation. Neurology. 2013;80(16):1494–500.CrossRef

34.

Ueno H , Kikumto M, Takebayashi Y, Ishibashi H, et al. Pomalidomide-associated PML in multiple myeloma: cortical susceptibility-weighted imaging hypointense findings prior to clinical deterioration 2020;26(3):452-455. https://doi.org/10.1007/s13365-020-00845-0

35.

•• Cortese I, Muranski P, Enose-Akahata Y, Ha S-K, Smith B. Pembrolizumab treatment for progressive multifocal leukoencephalopathy. NEJM. 2019;380:1597–605 Since this publication, there have been case reports and a small series of similar responses of PML to this PD-1 inhibitor.CrossRef

36.

Williamson EM, Berger JF. Central nervous system infections with immunomodulatory therapies. Continuum. 2015;21(6):1577–98.PubMed

37.

•• Luna G, Alping P, Burman J, Fink K, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77(2):184–91 This study based on a nationwide register-based cohort in Sweden found that compared with interferon beta and glatiramer, the off-label use of rituximab was associated with the highest risk of serious infections (both systemic and CNS). More patients on natalizumab and fingolimod received herpes antivirals. Subclinical carryover of natalizumab explained the two cases of PML in patients with fingolimod and rituximab, respectively.CrossRef

38.

Disanto G, Ripellino P, Riccitelli GC, et al. De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis. Mult Scler. 2020. https://doi.org/10.1177/1352458520952036. Online ahead of print.

39.

Chisari CG, Grimaldi LM, Salemi G, Ragonese P, Iaffaldano P, Bonavita S, et al. Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2020;91:1297–303.CrossRef

40.

Berger JR. Classifying PML risk with disease modifying therapies. Mult Scler Rel Dis. 2017;12:59–63.CrossRef

41.

Stefoski D, Balabanov R, Waheed R, Ko M, et al. Treatment of natalizumab-associated PML with filgrastim. Ann Clin Transl Neuro. 2019;6(5):923–31.CrossRef

42.

Ruggieri S, Logoteta A, Martini G, Bozzao A, DeGiglio L. Listeria monocytogenes–induced rhombencephalitis in a patient with multiple sclerosis treated with dimethyl fumarate. JAMA Neurol. 2018;75:762–3.CrossRef

43.

Thomas K, Schultheiss T, Ziemssen T. Neuroborreliosis during natalizumab treatment in multiple sclerosis. Neurology. 2013;81:1012–3.CrossRef

44.

Arvin AM, Wolinsky JS, Kappos L, Morris MI, Reder AT, Tornatore C, et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015;72(1):31–9.CrossRef

45.

Grebenciucova E, Pruitt A. Infections in patients receiving multiple sclerosis disease-modifying therapies. Curr Neurol Neurosci Rep. 2017;17:88.CrossRef

46.

Center for Disease Control and Prevention (CDC): recommended adult immunization schedule, United States. 2017.

47.

Bar-Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study. Neurology. 2020;95(14):1999–2008.CrossRef

48.

•• Farez MF, Correale J, Armstrong MG, Rae-Grant A, et al. Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis. Neurology. 2019;93:584–94. https://doi.org/10.1212/WNL0000000000008157An important reference for practicing clinicians. It is hard to give definitive advice about mRNA COVID-19 vaccinations at the time of this writing (see text).CrossRefPubMed

Titel: Central Nervous System Infections in Immunocompromised Patients
verfasst von: Amy A. Pruitt
Publikationsdatum: 01.07.2021
Verlag: Springer US
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 7/2021
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-021-01119-w

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2021

Cluster Headache: A Review and Update in Treatment

Effects of the Menstrual Cycle on Neurological Disorders

Effects of Obstructive Sleep Apnea and CPAP on Cognitive Function

Nutraceuticals and Behavioral Therapy for Headache

Sleep Disorders in Mitochondrial Diseases